[
  {
    "criterion": "Defines the types of success with the chemotherapeutic regimen by mentioning overall survival and disease-free survival.",
    "points": 5,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  },
  {
    "criterion": "Gives ranges of overall survival and disease-free survival.",
    "points": 4,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Gives further reading references when the user wanted exact figures/percentages.",
    "points": -2,
    "tags": [
      "level:example",
      "axis:instruction_following"
    ]
  },
  {
    "criterion": "Describes that the success of 5-FU + Leucovorin can be assessed by 5-year disease-free survival and 5-year overall survival.",
    "points": 9,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Mentions the 5-year overall survival and 5-year disease-free survival rates of notable trials, such as the National Surgical Adjuvant Breast and Bowel Project (NSABP C-04 & NSABP C-06), INT-0035, and the MOSAIC trial.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "States that the current standard of care includes adjuvant treatments like FOLFOX and CAPOX, with better success rates.",
    "points": 6,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Fails to state the success rate of 5-FU + Leucovorin.",
    "points": -10,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  },
  {
    "criterion": "Hedges on giving an exact estimate for the success rate of 5FU + Leucovorin in stage 3 colon cancer. (Justification: Different clinical trials give different data estimates, therefore final estimates are usually ranges based on data from multiple trials.)",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Shares that estimates from studies are population averages and that exact disease-free survival and overall survival data for each patient are variable.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Does not explicitly mention that combination regimens such as FOLFOX and CAPOX are the current standard of care based on higher disease-free and overall survival rates.",
    "points": -6,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  }
]